Ticker

No recent analyst price targets found for SCLX.

Latest News for SCLX

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in…

GlobeNewsWire • Jan 30, 2026
Scilex (NASDAQ:SCLX) Trading Up 8.8% – Time to Buy?

Scilex Holding Company (NASDAQ: SCLX - Get Free Report) was up 8.8% during trading on Thursday. The stock traded as high as $11.95 and last traded at $11.53. Approximately 106,019 shares changed hands during mid-day trading, an increase of 58% from the average daily volume of 66,936 shares. The stock had previously closed at $10.60.

Defense World • Jan 23, 2026
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment…

PRNewsWire • Jan 7, 2026
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc…

GlobeNewsWire • Jan 2, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for SCLX.

No House trades found for SCLX.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top